Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups. Devos D, et al. Among authors: devedjian jc. J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7. J Neural Transm (Vienna). 2020. PMID: 31912279 Free article. Review.
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Pérez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garçon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D. Moreau C, et al. Among authors: devedjian jc. Antioxid Redox Signal. 2018 Sep 10;29(8):742-748. doi: 10.1089/ars.2017.7493. Epub 2018 Feb 8. Antioxid Redox Signal. 2018. PMID: 29287521 Free PMC article. Clinical Trial.
Intracerebroventricular dopamine for Parkinson's disease.
Devos D, Devedjian JC, Moreau C. Devos D, et al. Among authors: devedjian jc. Oncotarget. 2017 Jul 11;8(28):45034-45035. doi: 10.18632/oncotarget.17596. Oncotarget. 2017. PMID: 28484085 Free PMC article. No abstract available.
Iron as a therapeutic target for Parkinson's disease.
Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Moreau C, et al. Among authors: devedjian jc. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Mov Disord. 2018. PMID: 29380903 Review. No abstract available.
A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis.
Devos D, Moreau C, Kyheng M, Garçon G, Rolland AS, Blasco H, Gelé P, Timothée Lenglet T, Veyrat-Durebex C, Corcia P, Dutheil M, Bede P, Jeromin A, Oeckl P, Otto M, Meininger V, Danel-Brunaud V, Devedjian JC, Duce JA, Pradat PF. Devos D, et al. Among authors: devedjian jc. Sci Rep. 2019 Feb 27;9(1):2918. doi: 10.1038/s41598-019-39739-5. Sci Rep. 2019. PMID: 30814647 Free PMC article. Clinical Trial.
Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis.
Gouel F, Timmerman K, Gosset P, Raoul C, Dutheil M, Jonneaux A, Garçon G, Moreau C, Danel-Brunaud V, Duce J, Burnouf T, Devedjian JC, Devos D. Gouel F, et al. Among authors: devedjian jc. Biomaterials. 2022 Jan;280:121311. doi: 10.1016/j.biomaterials.2021.121311. Epub 2021 Dec 4. Biomaterials. 2022. PMID: 34952382 Free article.
54 results